Milan Mishkovikj, Vice-President, Program Manager, and Volunteer at Hepar Centar Bitola, and Board Director at ELPA, shared a post on LinkedIn:
“From Paris to All of Europe – Action for Liver Health Starts Now!
At the 11th Paris MASH Meeting ( Institut Pasteur), global leaders in science, corporate leaders, and patient advocacy came together to shape the future of liver health.
The scientific program brought cutting-edge insights:
- How MASLD/ MASH impacts cancer risk and mortality.
- The global policy implications for patients.
- The role of comorbidities, genetics, and transplantation.
- The urgent need to integrate screening, monitoring, and individualized strategies.
ELPA was proud to stand at this table of innovation — presenting our European Liver Screening Week 2024 results and announcing the 2025 edition under the patronage of the European Parliament.
Together with friends and partners like Arun Sanyal, Lawrence Serfaty, Homie Razavi, Michael Betel, Selly Sickout, and many more, we showed that science, policy, corporatepartners, and patients must unite.
Now is the time for Europe to:
Put liver health high on the public health agenda.
Expand early screening programs.
Tackle the links between MASLD, MASH cancer, cardiovascular, obesity diabetes and kidney diseases.”
More from Milan Mishkovikj on OncoDaily.
